Heerma Peter 4
4 · Travere Therapeutics, Inc. · Filed Feb 12, 2025
Insider Transaction Report
Form 4
Heerma Peter
CHIEF COMMERCIAL OFFICER
Transactions
- Exercise/Conversion
Common Stock
2025-02-10+8,000→ 130,708 total - Sale
Common Stock
2025-02-11$25.00/sh−3,074$76,850→ 127,634 total - Sale
Common Stock
2025-02-12$23.53/sh−2,568$60,426→ 125,066 total - Exercise/Conversion
Performance-based restricted stock units
2025-02-10−8,000→ 0 total→ Common Stock (8,000 underlying)
Footnotes (4)
- [F1]On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 8,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain clinical/regulatory performance criteria. On February 10, 2025, the PSUs vested upon the Issuer's confirmation that the clinical/regulatory performance criteria had been satisfied, including confirming a path forward for submitting an sNDA for traditional approval of FILSPARI (sparsentan) in FSGS.
- [F2]Each PSU represents a contingent right to receive one share of the common stock of the Issuer.
- [F3]This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- [F4]Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.